Botulinum Toxin Purification Without Lyophilization or Precipitation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for purifying botulinum toxin suffer from low resolution, low yield, operational difficulties, scalability issues, and require reconstitution before administration, which can lead to contamination risks and loss of physician time.
Innovation Solution
A method involving multiple chromatography steps, including anion and cation exchange chromatography, followed by size exclusion chromatography, to purify botulinum toxin without precipitation, centrifugation, or lyophilization, resulting in a high-purity, stable form suitable for direct administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If precipitation techniques are used to purify botulinum toxin, then the toxin can be separated from residual impurities, but the resolution is low, yield is low, and operational control is difficult
Solution Approach 1:
The patent replaces mechanical/chemical precipitation methods with chromatography-based separation. Specifically, it uses ion exchange chromatography (anion and cation exchange columns) and size exclusion chromatography to separate botulinum toxin from impurities based on charge and size properties, achieving high resolution and controlled purification without the operational difficulties of precipitation techniques
Solution Approach 2:
The patent changes the separation parameters from precipitation (based on solubility changes with temperature or pH) to chromatography-based parameters including ion exchange capacity, molecular size, and shape. This allows for precise control over the purification process and high-resolution separation of toxin from complexes and impurities
2Stability of the object's composition
If lyophilization is used to store botulinum toxin, then stability is improved, but the toxin must be reconstituted before administration, creating contamination risks and losing physician time
Solution Approach 1:
The patent extracts and removes the lyophilization step from the purification process entirely. Instead of drying and freezing the toxin to create a stable powder form, it maintains the toxin in a stable liquid or aqueous form throughout the purification and storage process, eliminating the need for reconstitution while preserving stability
Solution Approach 2:
The patent inverts the conventional approach by not using lyophilization to achieve stability. Instead, it achieves stability through controlled purification conditions, proper formulation, and storage at appropriate temperatures, allowing the toxin to remain ready for immediate administration without time-consuming reconstitution
3Manufacturing precision
If multiple purification steps are added to improve purity, then the toxin can be freed from animal products, but the process complexity increases
Solution Approach 1:
The patent segments the purification process into distinct functional stages: ion exchange chromatography for charge-based separation, size exclusion chromatography for molecular size separation, and filtration steps. Each segment targets specific impurities (animal products, protein complexes, aggregates) and can be independently optimized, achieving high purity without requiring an excessive number of sequential steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high-yield, high-purity botulinum toxin free from animal products, eliminating the need for reconstitution and reducing contamination risks, while maintaining toxin stability and activity.
Implementation Method 1
The first chromatography column is an anion exchange column
Implementation Method 2
The second chromatography column is a cation exchange column
Implementation Method 3
The third chromatography column is a size exclusion column
Data Source
AI summary
The present technology relates to commercial-scale methods for purifying botulinum toxin compositions obtained from cell cultures. Purification methods according to the present disclosure are based on a series of filtration and chromatographic separation steps that produce a high-purity botulinum toxin composition, which comprises botulinum toxin protein molecules (˜150 kDa) in solution, which is free, essentially free, or substantially free of botulinum toxin complexes and animal products, and without precipitating or lyophilizing botulinum toxin protein molecules. The purification method according to the present disclosure uses no precipitation, lyophilization, or centrifugation steps, permitting production of highly pure, highly active, free botulinum toxin protein molecules (˜150 kDa) in solution, without the need for reconstitution by the end user.